$NEOG

Neogen (NEOG) reported fiscal Q4 2026 revenue of $225.3 million, up 4.3% in core growth, led by Food Safety. Adjusted gross margin rose to 49.7% and adjusted EBITDA grew 12% to $45.4 million. FY2027 guidance: revenue $880-$885 million and adjusted EBITDA $180-$182 million. The company plans a 50% R&D increase and a $140 million genomics divestiture for debt reduction.

NEOGEN CORP (NEOG) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K false 0000711377 0000711377 2026-08-03 2026-08-03 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 03

The following biotech stocks reached 52-week highs on July 30, 2026, driven by key catalysts such as positive quarterly reports or announced settlement agreements. Corcept Therapeutics Incorporated (CORT) Corcept is a biopharmaceutical company engaged in developing medications for metabolic, oncologic, and neurologic diseases. Shares surged over 30% on Thursday to a 52-week high of $122.21.

Today's top gainers included Glucotrack, whose subsidiary announced progress in the development strategy for LT-100, a novel non-narcotic therapy; Nuwellis, following expanded clinical recognition for its Aquadex therapy; Bausch Health, after reporting strong second-quarter 2026 results and raising its outlook; and Corcept Therapeutics, after posting robust second-quarter 2026 results, among others. Read on… GCTK's LT-100 Program Moves Forward Glucotrack Inc.

Neogen (NASDAQ: NEOG) reported Q2 CY2026 results. Revenue was $225.3 million, flat year over year but 6% above estimates. Full-year revenue guidance midpoint was $882.5 million, 3.9% above analysts’ forecasts. Non-GAAP EPS was $0.09, 58.8% above consensus. The stock rose 7.1% to $10.07 after results.

NEOGEN CORP (NEOG) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 neog-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Neogen Reports Fourth Quarter and Full Fiscal Year 2026 Financial Results Delivered Strong Core Growth in Q4 FY26 with Food Safety Core Growth Highest Since FY23 • Fiscal fourth quarter 2026 revenue of $225.3 million represen

Neogen Chemicals reported unaudited consolidated Q1 FY27 results for the quarter ended June 30, 2026. Revenue from operations rose 34.04% YoY to ₹250.29 crore. Net profit increased 66.76% YoY to ₹17.11 crore, with operating margin at 19.35%. The company said net worth rose to ₹984.47 crore and debt equity improved to 1.40x. Shares last traded on BSE near ₹2,063.

Analysts covered healthcare stocks Cardinal Health (CAH) and Neogen (NEOG). Bank of America Securities’ Allen Lutz reiterated a Buy on CAH with a $260 price target; CAH closed at $225.96. TipRanks cites consensus Strong Buy and a $251.80 target. William Blair’s Brandon Vazquez kept a Hold on NEOG, which closed at $10.00; consensus is Moderate Buy with a $12 target.

A recent StockStory analysis evaluates three companies receiving significant attention from Wall Street, cautioning against overly optimistic price targets from analysts. The report recommends selling Wynn Resorts and Neogen based on revenue growth, free cash flow, debt ratios, and market challenges. Conversely, Bowhead Specialty Holdings is identified as a stock likely to meet or exceed expectations due to its strong market position.

This article analyzes the Q4 earnings performance of Abbott Laboratories (NYSE:ABT) and other diversified medical device and supplies companies. Abbott Laboratories reported revenues that missed analyst expectations by 2.9% and saw its stock fall 9.6%. In contrast, Neogen (NASDAQ:NEOG) achieved the strongest performance, beating revenue estimates by 7.2% and seeing its stock rise 33.8%.